Lite Strategy Inc (Lite Strategy) is a pharmaceutical company focused on developing novel and differentiated cancer therapies.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lite Strategy's Research and Development (R&D) program is focused on generating data to meet medical needs and developing a clinical and commercial profile with attractive attributes. This is achieved through pre-clinical studies and clinical trial programs. Key aspects of the R&D program include characterizing the molecular targets of action for drug candidates, evaluating the therapeutic benefits and indications for use of drug candidates, and determining the most appropriate therapeutic indications and dosage forms for drugs like voruciclib or zandelisib based on pre-clinical findings. The company operates in a highly regulated environment, with substantial requirements imposed by the US Food and Drug Administration (FDA) and comparable agencies in other countries on research, development, testing, and commercialization of pharmaceutical products. Overall, Lite Strategy's R&D efforts are aimed at advancing its drug candidates through rigorous scientific and regulatory processes, despite the financial and operational challenges inherent in the pharmaceutical industry. In FY2025, the company incurred expenses of US$3.9 million on R&D.